|The MA Prescription Drug Monitoring Program (PMP) provides prescribers with prior 12 month history of a patient's narcotic, benzodiazepine and amphetamine-type stimulant prescriptions. All prescribers of these medications SHOULD BE PMP ENROLLED. Practice delegates can also be enrolled to access PMP information. Throughout 2016 PMP will transform into an improved on-line tool called MassPAT (Massachusetts Prescription Awareness Tool) with the following changes:
- Streamlined log-in
- Multi-state info
- Simplified Delegate Enrollment & Usage
- 24 Hour Data
- EMR Integration
All prescribers, unless specifically exempted, are REQUIRED to use the prescription monitoring program in the following circumstances:
* Prior to prescribing a narcotic drug in Schedule II or III to a patient for the first time
* Each time the prescriber issues a prescription to a patient for any drug in Schedule II or III that "has been determined by the Department of Public Health to be commonly misused or abused and which has been designated as a drug that needs additional safeguards in guidance to be issued by the Department of Public Health;" (DPH states these are currently only Schedule II and II narcotics; stimulants such as Adderall are CURRENTLY excluded)
* Prior to prescribing a benzodiazepine to a patient for the first time.
Prescribers are NOT REQUIRED to use the PMP in the following circumstances:
* When providing medical care to hospice patients
* When treating a patient in an Emergency Department and prescriber does not anticipate writing a prescription for a controlled substance in Schedules II through V during that encounter with the patient; OR prescribe more than a five-day supply of a controlled substance in Schedules II through V
* When emergency care is required and, in prescriber's professional opinion, utilization of the prescription monitoring program is likely to result in patient harm
* When providing medical care to hospital inpatients
* When delivering a controlled substance in a single dose or in a quantity that is essential for the immediate and proper treatment of the patient, until it is possible for the patient to have a prescription filled by a pharmacy;
* When it is not reasonably possible to use the PMP, including when the system is not operational due to temporary technological or electrical failure;
* When examining or treating a pediatric patient who is less than 8 years old.
Prescribers are encouraged to use a Consent Form
for chronic opioid therapy.
Per 2016 MA Opioid Prescribing Requirements, a Pain Management Agreement
is required when prescribing extended-release opioids such as Oxycontin. The agreement includes patient agreement to urine and serum toxicology screens at the prescribers discretion.